Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06632951
Title Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (LIVIGNO-3)
Acronym LIVIGNO-3
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR

Facility Status City State Zip Country Details
Highlands Oncology Group - Springdale /ID# 270290 RECRUITING Springdale Arkansas 72762 United States Details
Tel Aviv Sourasky Medical Center /ID# 270106 RECRUITING Tel Aviv Tel-Aviv 6423906 Israel Details
Rabin Medical Center /ID# 270107 RECRUITING Haifa 4941492 Israel Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field